Back to top
more

Sage Therapeutics (SAGE)

(Real Time Quote from BATS)

$14.66 USD

14.66
240,120

+0.97 (7.09%)

Updated Apr 29, 2024 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SAGE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Sage Therapeutics, Inc. [SAGE]

Reports for Purchase

Showing records 121 - 140 ( 152 total )

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 121

03/09/2020

Daily Note

Pages: 7

AAN 2020 Preview - Looking Ahead To Toronto

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 122

02/28/2020

Company Report

Pages: 5

Hurry Up and Wait for Clarity on Zulranolone; Lower Target to $78; Stay Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 123

02/27/2020

Company Report

Pages: 9

Waiting Is The Hardest Part; Uneventful 4Q19 As SAGE Waits For FDA Feedback

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 124

01/31/2020

Industry Report

Pages: 16

The Monthly Check-Up

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 125

01/27/2020

Daily Note

Pages: 24

Let''s Get It Started: 4Q19 Commercial Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 126

12/16/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 127

12/16/2019

Company Report

Pages: 16

Could Lower Exposure Explain SAGE-217/MOUNTAIN Miss?

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 128

12/06/2019

Company Report

Pages: 6

SAGE-217 Steps Into a Crevasse on the Way to the Summit; Lower Target, Reiterate Neutral Rating

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 129

12/05/2019

Company Report

Pages: 7

Now, We''re Depressed - MOUNTAIN Fails To Meet Primary Endpoint

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 130

11/29/2019

Industry Report

Pages: 12

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 131

11/20/2019

Industry Report

Pages: 7

Perspectives from KOL Dinner on Major Depressive Disorder

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 132

11/13/2019

Company Report

Pages: 5

Getting Out of Mountain''s Shadow

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 133

11/12/2019

Company Report

Pages: 9

Moving MOUNTAINs - Pivotal Readout Timing Narrowed to 4Q19

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 134

10/30/2019

Company Report

Pages: 29

Scaling the Big Mountains in CNS; Initiate at Neutral With $160 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 75.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 135

10/14/2019

Daily Note

Pages: 25

Biotechnology - Down But Not Out: Looking Ahead to 3Q19 Biotech Reporting

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 136

08/16/2019

Industry Report

Pages: 10

Biotechnology - Overcoming Challenges in CNS Drug Development

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 137

08/06/2019

Company Report

Pages: 9

An Uneventful 2Q19 Report Following Pipeline Deep Dive

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 138

07/25/2019

Daily Note

Pages: 12

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 139

07/24/2019

Daily Note

Pages: 8

FutureCast Pulls Back Curtain on R-D Efforts

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 140

07/19/2019

Industry Report

Pages: 10

HEALTHCARE -The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party